PGI7 EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASH